Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Azafaros

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
From Azafaros
Via Business Wire
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing
From Azafaros
Via Business Wire
Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders
From Azafaros
Via Business Wire
Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference
From Azafaros
Via Business Wire
Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients
From Azafaros
Via Business Wire
Azafaros Appoints Chief Operating Officer and Head of Finance
From Azafaros
Via Business Wire
Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA
From Azafaros
Via Business Wire
Azafaros Receives FDA's IND Clearance and Fast Track Designation for Lead Asset AZ-3102
From Azafaros
Via Business Wire
Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease
From Azafaros
Via Business Wire
Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Conference
From Azafaros
Via Business Wire
Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis
From Azafaros
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.